#$%^&*AU2020100093A420200227.pdf#####ABSTRACT An embodiment of the present disclosure mainly relates to an isonicotinic acid derivative, a stereoisomer, a racemate, a tautomer, or a pharmaceutically acceptable salt thereof represented by the formula (I), a preparation method thereof, and its use in preparation of anticancer drugs. In formula (I), Z is selected from 0, S, and NR3, wherein R3 is hydrogen or CI-C6 alkyl； R1 is selected from C1 -C 6 alkyl, C1 -C 6 alkoxy, and halogenated C1 -C 6 alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, halogen； R2 is selected from halogen, cyano, nitro, C1 ~ C6 alkyl, C1 ~ C6 alkoxy or halogenated CI-C 6 alkyl； m is an integer from 0-4； n is an integer from 0-5； provided that when Z is selected from NR3 , m is 0, and n is 1, R2 is not halogen. 0 m(R1) (R2 )n N (I)
